Vicuron (NASDAQ:MICU)
Historical Stock Chart
From Oct 2019 to Oct 2024
Vicuron Pharmaceuticals to Present at the Lazard Freres & Co.
Healthcare Conference
KING OF PRUSSIA, Pa., Nov. 29 /PRNewswire-FirstCall/ -- Vicuron
Pharmaceuticals Inc. (Nasdaq and Nuovo Mercato: MICU) today announced that
George F. Horner III, President and Chief Executive Officer, will present at
the 1st Annual Lazard Freres & Co. Healthcare Conference at 10:00 a.m. Eastern
Standard Time on Tuesday, November 30, 2004 at the Mandarin Oriental Hotel in
New York City, New York.
To access the live audio broadcast or the subsequent archived recording log on
to http://www.vicuron.com/ and click on the investor relations section. Please
connect to the website several minutes prior to the start of the webcast to
ensure adequate time for any software download that may be necessary. The live
broadcast will be archived for 30 days. About Vicuron
Vicuron Pharmaceuticals is a biopharmaceutical company focused on discovering,
developing, manufacturing and commercializing vital medicine for seriously ill
patients. In May 2004, Vicuron received an approvable letter from the FDA for
its lead product anidulafungin for the treatment of esophageal candidiasis. The
company's other lead product, dalbavancin, a novel intravenous antibiotic for
the treatment of serious Gram-positive infections, has completed Phase 3
clinical trials. The company's versatile research engine integrates
industry-leading expertise in functional genomics, natural products discovery,
mechanism-based drug design and combinatorial and medicinal chemistry. These
approaches are yielding promising novel and next-generation compounds, many of
which are in the later stages of preclinical development. In addition, the
company has research and development collaborations with leading pharmaceutical
companies, such as Pfizer and Novartis.
Forward-Looking Statements
This news release contains forward-looking statements that predict or describe
future events or trends. The matters described in these forward- looking
statements are subject to known and unknown risks, uncertainties and other
unpredictable factors, many of which are beyond Vicuron's control. Vicuron
faces many risks that could cause its actual performance to differ materially
from the results predicted by its forward-looking statements, including the
possibilities that clinical trials and the results thereof might be delayed, or
unsuccessful, that the timing of the filing of any new drug application or any
amendment to a new drug application might be delayed, that clinical trials
might indicate that a product candidate is unsafe or ineffective, that the FDA
might require additional information to be submitted and additional actions to
be taken before it will make any decision, that any filed new drug application
may not be approved by the FDA, that ongoing proprietary and collaborative
research might not occur or yield useful results, that the pipeline may not
yield a new clinical candidate or a commercial product, that a third party may
not be willing to license our product candidates on terms acceptable to us or
at all, that competitors might develop superior substitutes for Vicuron's
products or market these competitive products more effectively, that a sales
force may not be developed as contemplated and that one or more of Vicuron's
product candidates may not be commercialized successfully. The reports that
Vicuron files with the U.S. Securities and Exchange Commission contain a fuller
description of these and many other risks to which Vicuron is subject. Because
of those risks, Vicuron's actual results, performance or achievements may
differ materially from the results, performance or achievements contemplated by
its forward- looking statement. The information set forth in this news release
represents management's current expectations and intentions. Vicuron assumes no
responsibility to issue updates to the forward-looking matters discussed in
this news release.
DATASOURCE: Vicuron Pharmaceuticals Inc.
CONTACT: Dov A. Goldstein, M.D. of Vicuron Pharmaceuticals Inc.,
+1-610-205-2312, or ; or Hala Mirza of WeissComm
Partners, +1-212-204-2080, or , or Aline Schimmel of
Burns McClellan Inc., +1-212-213-0006, or , both for
Vicuron Pharmaceuticals Inc.
Web site: http://www.vicuron.com/